Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid in Neuroblastoma and Neuroendocrine Tumors
NCT01048086Phase 2Withdrawn
- Sponsor
- University of Iowa
- Start
- Jun 2009
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neuroblastoma and Neuroendocrine Neoplasm (NEN) comparing Retinoic Acid with Placebo (2 arms). Primary endpoint: Tumor Response. Planned start Jun 2009; status: withdrawn.
02
Drugs
tretinoin
03
Conditions
neuroblastomaNeuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01048086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01048086.